U.S. markets closed
  • S&P 500

    3,768.47
    -51.25 (-1.34%)
     
  • Dow 30

    30,924.14
    -345.95 (-1.11%)
     
  • Nasdaq

    12,723.47
    -274.28 (-2.11%)
     
  • Russell 2000

    2,146.92
    -60.87 (-2.76%)
     
  • Crude Oil

    64.39
    +0.56 (+0.88%)
     
  • Gold

    1,695.60
    -5.10 (-0.30%)
     
  • Silver

    25.44
    -0.02 (-0.08%)
     
  • EUR/USD

    1.1967
    -0.0100 (-0.83%)
     
  • 10-Yr Bond

    1.5500
    +0.0800 (+5.44%)
     
  • GBP/USD

    1.3889
    -0.0064 (-0.46%)
     
  • USD/JPY

    107.9870
    +0.9850 (+0.92%)
     
  • BTC-USD

    48,534.86
    -2,510.01 (-4.92%)
     
  • CMC Crypto 200

    968.73
    -18.48 (-1.87%)
     
  • FTSE 100

    6,650.88
    -24.59 (-0.37%)
     
  • Nikkei 225

    28,930.11
    -628.99 (-2.13%)
     

Zynerba Pharmaceuticals (ZYNE) Jumps: Stock Rises 7.7%

  • Oops!
    Something went wrong.
    Please try again later.
Zacks Equity Research
·2 min read
  • Oops!
    Something went wrong.
    Please try again later.

Zynerba Pharmaceuticals, Inc. ZYNE was a big mover last session, as the company saw its shares rise nearly 8% on the day. The move came on solid volume too with far more shares changing hands than in a normal session. The stock picked up sharply from the near-flat trend of $3.51 to $3.87 in the past one-month time frame.

The company has seen one negative estimate revision in the past few weeks, while its Zacks Consensus Estimate for the current quarter has also moved lower over the past few weeks, suggesting there may be trouble down the road. So, make sure to keep an eye on this stock going forward, to see if this recent move higher can last.

Zynerba Pharmaceuticals currently has a Zacks Rank #3 (Hold) while its Earnings ESP is negative.


Investors interested in the Medical - Generic Drugs industry may consider Acasti Pharma Inc ACST, which has a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

The Hottest Tech Mega-Trend of All

Last year, it generated $24 billion in global revenues. By 2020, it's predicted to blast through the roof to $77.6 billion. Famed investor Mark Cuban says it will produce "the world's first trillionaires," but that should still leave plenty of money for regular investors who make the right trades early.

See Zacks' 3 Best Stocks to Play This Trend >>


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
 
Acasti Pharma, Inc. (ACST) : Free Stock Analysis Report
 
Zynerba Pharmaceuticals, Inc. (ZYNE) : Free Stock Analysis Report
 
To read this article on Zacks.com click here.
 
Zacks Investment Research